TY - JOUR
T1 - An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis
AU - Gribetz, Carin H.
AU - Blum, Robin
AU - Brady, Christopher
AU - Cohen, Steven
AU - Lebwohl, Mark
N1 - Funding Information:
Supported by Biogen Idec Inc.
PY - 2005/7
Y1 - 2005/7
N2 - Background: The efficacy and safety of one and two courses of alefacept have been demonstrated in phase 2 and 3 clinical trials, with a course of alefacept defined as 12 weeks of once-weekly treatment followed by 12 weeks of observation. Methods: This randomized, single-center study compared the safety and efficacy of a standard 12-week versus extended 16-week alefacept dosing period in 20 patients with chronic plaque psoriasis. Results: Both dose groups showed marked improvement in mean Psoriasis Area and Severity Index (PASI) score from baseline through week 24 (between-group difference: not significant). In each group, 60% of patients achieved PASI 50 (≥50% reduction from baseline PASI score) at any time between weeks 12 and 24. For patients who received 16 weeks of alefacept, the mean percentage change from week-12 PASI score was higher and continued to increase through week 24 compared with that for patients who received 12 weeks of alefacept (P <. 05). Adverse events were similar between the two groups and comparable with those observed in phase 2 and 3 clinical studies of alefacept. Conclusions: This was an open-label, single-center study of 20 patients. Further study is warranted to assess the effect of alefacept when administered for more than 12 weeks. Extended dosing with alefacept appeared to have a similar safety profile to 12-week dosing and may offer further benefit to some patients for disease improvement.
AB - Background: The efficacy and safety of one and two courses of alefacept have been demonstrated in phase 2 and 3 clinical trials, with a course of alefacept defined as 12 weeks of once-weekly treatment followed by 12 weeks of observation. Methods: This randomized, single-center study compared the safety and efficacy of a standard 12-week versus extended 16-week alefacept dosing period in 20 patients with chronic plaque psoriasis. Results: Both dose groups showed marked improvement in mean Psoriasis Area and Severity Index (PASI) score from baseline through week 24 (between-group difference: not significant). In each group, 60% of patients achieved PASI 50 (≥50% reduction from baseline PASI score) at any time between weeks 12 and 24. For patients who received 16 weeks of alefacept, the mean percentage change from week-12 PASI score was higher and continued to increase through week 24 compared with that for patients who received 12 weeks of alefacept (P <. 05). Adverse events were similar between the two groups and comparable with those observed in phase 2 and 3 clinical studies of alefacept. Conclusions: This was an open-label, single-center study of 20 patients. Further study is warranted to assess the effect of alefacept when administered for more than 12 weeks. Extended dosing with alefacept appeared to have a similar safety profile to 12-week dosing and may offer further benefit to some patients for disease improvement.
UR - http://www.scopus.com/inward/record.url?scp=20444492267&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20444492267&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2005.03.053
DO - 10.1016/j.jaad.2005.03.053
M3 - Article
C2 - 15965424
AN - SCOPUS:20444492267
SN - 0190-9622
VL - 53
SP - 73
EP - 75
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 1
ER -